Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005579
Abstract: Key Points Blinatumomab was associated with low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%). The best blinatumomab outcomes were seen in patients… read more here.
Keywords: blinatumomab pediatric; refractory cell; cell acute; pediatric relapsed ... See more keywords